Dear Valued Partners,

 

Warm greetings from Raphas, a leading manufacturer of high-quality microneedle patches.

 

As we approach the final month of a dynamic and eventful 2025,

we would like to take this opportunity to thank you for your continued interest and trust.



Looking ahead to 2026, Raphas remains fully committed to supporting

your new product development with proven technology, reliability, and long-term partnership.

Please feel free to reach out to us at any time should you wish to explore new opportunities together.

 

1. Trust Proven by Global Certifications

Raphas operates under industry-leading quality standards and holds

multiple internationally recognized certifications,

including ISO 22716 (Cosmetic GMP) and ISO 13485 (Medical Device Manufacturing).

 

With our strategic focus on expanding into pharmaceutical-grade technologies,

we apply drug-level quality control systems across all processes,

including cosmetic manufacturing, ensuring a higher level of safety, consistency,

and technical sophistication compared to conventional cosmetic manufacturers.

 

In addition, we have recently obtained ISO 9001 certification,

further validating our standardized and reliable operational processes.



Backed by these certifications and our status as a KOSDAQ-listed company,

Raphas is well positioned to support your brand with transparency and confidence.

 

2. In-House Clinical Expertise with Clear, Data-Driven Results

Raphas owns a specialized dermatological clinical institute with one of

the most extensive microneedle testing experiences in Korea.

This enables us to conduct early efficacy validation, consumer testing,

and human application studies efficiently and accurately during development.

 

Clinical data plays a critical role not only in ODM development but also in product credibility and marketing.

Our clinical-driven approach provides measurable results that directly enhance product value and market competitiveness.

 

3. Market-Proven Performance Recognized by Consumers

Raphas’ technology has already been validated in the market.

Our flagship in-house brands have won the Olive Young Awards for topical patches for six consecutive years, demonstrating strong consumer trust and preference within Korea’s leading H&B retail channel.

 

This recognition reflects real consumer choice and confirms

both the efficacy and commercial potential of microneedle products.

Beyond manufacturing, Raphas brings extensive experience in

product strategy and market executionto support your brand’s success.

 

Thank you sincerely for your trust and interest throughout 2025. In the coming year,

Raphas will continue to deliver enhanced quality systems,

clinically proven results, and consumer-validated product performance

to help strengthen your brand and drive sustainable growth.

 

We look forward to building a long-term partnership and growing together.

Wishing you a warm, healthy, and successful year-end.

 

Kind regards,

Raphas